HIV Cure Status 2024: Remission Cases, Gene Therapy & Ongoing Research
No scalable cure exists, but remarkable progress defines the landscape.
Current Standard: ART
- Combination antiretroviral therapy (ART) suppresses HIV to undetectable (<50 copies/mL).
- U=U: Undetectable = Untransmittable (sexual transmission).
- Life expectancy near-normal with early, sustained treatment.
- Long-acting injectables (cabotegravir/rilpivirine q2mo) improve adherence.
Documented Remission Cases (Not Scalable Cures)
- Berlin Patient (Timothy Ray Brown): CCR5Δ32/Δ32 stem cell transplant for AML. Cured HIV; died 2020 from leukemia relapse.
- London Patient (Adam Castillejo): Similar transplant; in remission since 2019.
- Düsseldorf, New York, City of Hope patients: Additional CCR5Δ32 transplants with sustained remission.
- Mississippi Baby / Visconti Cohort: Early ART → post-treatment control (not eradication).
Active Cure Strategies
| Strategy | Mechanism | Status |
|---|---|---|
| "Shock & Kill" (Latency reversal) | LRAs (HDACi, PKC agonists) reactivate reservoir → immune clearance | Phase I/II; limited reservoir reduction |
| "Block & Lock" (Deep latency) | Tat inhibitors, epigenetic silencers → permanent silencing | Preclinical |
| Gene editing (CRISPR/Cas9) | Excise provirus, CCR5 knockout | Animal models; early human trials (EBT-101) |
| Broadly neutralizing antibodies (bNAbs) | Target conserved Env epitopes; Fc-mediated clearance | Phase II; some post-ART control |
| Therapeutic vaccines | Boost HIV-specific T/B cell responses | Multiple Phase I/II; modest immunogenicity |
| Stem cell / CAR-T | Engineered HIV-resistant hematopoiesis | Preclinical/early phase |
